These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19660004)

  • 1. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.
    Lowe PJ; Tannenbaum S; Gautier A; Jimenez P
    Br J Clin Pharmacol; 2009 Jul; 68(1):61-76. PubMed ID: 19660004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.
    Lowe PJ; Georgiou P; Canvin J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):68-77. PubMed ID: 25497995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
    Kornmann O; Watz H; Fuhr R; Krug N; Erpenbeck VJ; Kaiser G
    Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
    Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
    J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.
    Sheldon E; Schwickart M; Li J; Kim K; Crouch S; Parveen S; Kell C; Birrell C
    Adv Ther; 2016 Feb; 33(2):225-51. PubMed ID: 26843086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on omalizumab in allergic asthma.
    Bang LM; Plosker GL
    BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
    Zhu R; Zheng Y; Putnam WS; Visich J; Eisner MD; Matthews JG; Rosen KE; D'Argenio DZ
    AAPS J; 2013 Apr; 15(2):559-70. PubMed ID: 23413101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents.
    Sorkness CA; Wildfire JJ; Calatroni A; Mitchell HE; Busse WW; O'Connor GT; Pongracic JA; Ross K; Gill MA; Kattan M; Morgan WJ; Teach SJ; Gergen PJ; Liu AH; Szefler SJ
    J Allergy Clin Immunol Pract; 2013 Mar; 1(2):163-71. PubMed ID: 24565455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
    Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab for asthma in adults and children.
    Normansell R; Walker S; Milan SJ; Walters EH; Nair P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
    Lowe PJ; Renard D
    Br J Clin Pharmacol; 2011 Aug; 72(2):306-20. PubMed ID: 21392073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy.
    Baker DL; Peng K; Cheu M; Fischer SK
    Curr Med Res Opin; 2014 May; 30(5):913-22. PubMed ID: 24354863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
    Bousquet J; Wenzel S; Holgate S; Lumry W; Freeman P; Fox H
    Chest; 2004 Apr; 125(4):1378-86. PubMed ID: 15078749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab is effective in the long-term control of severe allergic asthma.
    Lanier BQ; Corren J; Lumry W; Liu J; Fowler-Taylor A; Gupta N
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):154-9. PubMed ID: 12952109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab: a review of its use in the management of allergic asthma.
    Bang LM; Plosker GL
    Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.